Table 1.
Baseline characteristics according to clinical outcomes.
| No ischemic event (n=8815) |
Ischemic event (n=595) |
No bleeding event (n=9150) |
Bleeding event (n=260) |
|
|---|---|---|---|---|
| Age, mean ± SD | 62.1 ± 10.5 | 66.2 ± 11.2* | 62.2 ± 10.6 | 67.3 ± 10.1† |
| Male | 6705/8815 (76.1%) |
458/595 (77.0%) |
6691/9150 (76.4%) |
172/260 (66.2%)† |
| BMI (kg/m2), mean ± SD | 28.0 ± 4.6 | 28.4 ±5.7 | 28.1 ± 4.7 | 27.9 ± 5.6 |
| Active smoking | 2170/8814 (24.6%) |
151/595 (25.4%) |
2261/9149 (24.7%) |
60/260 (23.1%) |
| Hypertension | 5719/8815 (64.9%) |
441/595 (74.1%)* |
5967/9150 (65.2%) |
193/260 (74.2%)† |
| Diabetes | 2378/8815 (27.0%) |
262/595 (44.0%)* |
2548/9150 (27.9%) |
92/260 (35.4%)† |
| Prior MI | 1695/8815 (19.2%) |
175/595 (29.4%)* |
1820/9150 (19.9%) |
50/260 (19.2%) |
| Prior PCI | 1096/8815 (12.4%) |
96/595 (16.1%)* | 1161/9150 (12.7%) |
31/260 (11.9%) |
| Known PVD | 414/8815 (4.7%) | 53/595 (8.9%)* | 442/9150 (4.8%) |
25/260 (9.6%)† |
| Prior stroke | 261/8815 (3.0%) | 34/595 (5.7%)* | 283/9150 (3.1%) |
12/260 (4.6%) |
| Prior CABG | 446/8815 (5.1%) | 55/595 (9.2%)* | 484/9150 (5.3%) |
17/260 (6.5%) |
| Prior CHF | 260/8815 (3.0%) | 49/595 (8.2%)* | 289/9150 (3.2%) |
20/260 (7.7%)† |
| Creatinine clearance, mL/min ≥60 30–59 <30 Missing |
7099/8815(80.5%) 1120/8815 (12.7%) 44/8815 (0.5%) 552/8815 (6.3%) |
379/595 (63.7%)* 151/595 (25.4%)* 20/595 (3.4%)* 45/595 (7.6%)* |
7308/9150 (79.9%) 1196/9150 (13.1%) 56/9150 (0.6%) 590/9150 (6.4%) |
170/260 (65.4%)† 75/260 (28.9%)† 8/260 (3.1%)† 7/260 (2.7%)† |
| Presentation Stable angina NSTEACS STEMI |
5073/8815 (57.6%) 3077/8815 (34.9%) 665/8815 (7.5%) |
317/595 (53.3%)* 218/595 (36.6%)* 60/595 (10.1%)* |
5252/9150 (57.4%) 3194/9150 (34.9%) 704/9150 (7.7%) |
138/260 (53.1%) 101/260 (38.9%) 21/260 (8.1%) |
| Stent C-SES E-ZES |
3934/8815 (44.6%) 4881/8815 (55.4%) |
301/595 (50.6%)* 294/595 (49.4%)* |
4126/9150 (45.1%) 5024/9150 (54.9%) |
109/260 (41.9%) 151/260 (58.1%) |
| Left main PCI | 103/8815 (1.2%) | 13/595 (2.2%)* | 110/9150 (1.2%) |
6/260 (2.3%) |
| Lesion length > 18 mm |
3823/8809 (43.4%) |
299/595 (50.3%)* |
4007/9150 (43.8%) |
115/259 (44.4%) |
| Stent length | 31.1 ± 20.6 | 35.4 ± 24.2* | 31.3 ± 20.8 | 32.1 ± 23.3 |
| Vessel diameter ≤2.75 mm |
3500/8808 (39.7%) |
278/595 (46.7%)* |
3677/9144 (40.2%) |
101/259 (39.0%) |
| Bifurcation | 1854/8814 (21.0%) |
140/595 (23.5%) |
1939/9150 (21.2%) |
55/259 (21.2%) |
| Multivessel PCI | 1648/8815 (18.7%) |
145/595 (24.4%)* |
1751/9150 (19.1%) |
42/260 (16.2%) |
| SVG PCI | 27/8815 (0.3%) | 7/595 (1.2%)* | 33/9150 (0.4%) | 1/260 (0.4%) |
| In-stent restenosis | 124/8815 (1.4%) | 6/595 (1.0%) | 124/9150 (1.4%) | 6/260 (2.3%) |
| Stent number 0 1 2 ≥3 |
84/8815 (0.9%) 5191/8815 (58.9%) 2270/8815 (25.8%) 1270/8815 (14.4%) |
9/595 (1.5%)* 286/595 (48.1%)* 185/595 (31.1%)* 115/595 (19.3%)* |
86/9150 (0.9%) 5333/9150 (58.3%) 2386/9150 (26.1%) 1345/9150 (14.7%) |
7/260 (2.7%)† 144/260 (55.4%)† 69/260 (26.5%)† 40/260 (15.4%)† |
*
p<0.05 for the comparison of no ischemic event vs. ischemic event
†
p<0.05 for the comparison of no bleeding event vs. bleeding event
BMI, body-mass index; MI, myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; CABG, coronary artery bypass graft surgery; CHF, congestive heart failure; NSTEACS, non-ST elevation acute coronary syndrome; STEMI, ST elevation myocardial infarction; SVG, saphenous vein graft; C-SES, Cypher sirolimus eluting stent; E-ZES, Endeavor zotarolimus eluting stent.